{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:03:45Z","timestamp":1789549425136,"version":"build-2803163510"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["IHS-2017C3-9211"],"award-info":[{"award-number":["IHS-2017C3-9211"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K07CA216326"],"award-info":[{"award-number":["K07CA216326"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA211723"],"award-info":[{"award-number":["R01CA211723"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["KL2-TR-002385"],"award-info":[{"award-number":["KL2-TR-002385"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007273","name":"Weill Cornell Medical College","doi-asserted-by":"publisher","award":["UL1TR002384"],"award-info":[{"award-number":["UL1TR002384"]}],"id":[{"id":"10.13039\/100007273","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ygyno.2023.07.017","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T18:50:21Z","timestamp":1693335021000},"page":"72-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Partner and localizer of BRCA2 (PALB2) pathogenic variants and ovarian cancer: A systematic review and meta-analysis."],"prefix":"10.1016","volume":"177","author":[{"given":"Priyanka","family":"Narayan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Danyal","family":"Ahsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M.","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiza","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah R.","family":"Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedict","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanice","family":"Beaumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse T.","family":"Brewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Christos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Hickner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloise","family":"Chapman-Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Cantillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Holcomb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi N.","family":"Sharaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa K.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2023.07.017_bb0005","series-title":"Cancer Stat Facts: Ovarian Cancer [Internet]","year":"2023"},{"issue":"3","key":"10.1016\/j.ygyno.2023.07.017_bb0010","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ygyno.2023.07.017_bb0015","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1038\/ncomms4156","article-title":"Integrated analysis of germline and somatic variants in ovarian cancer","volume":"5","author":"Kanchi","year":"2014","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.ygyno.2023.07.017_bb0020","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMra1503523","article-title":"The role of risk-reducing surgery in hereditary breast and ovarian Cancer","volume":"374","author":"Hartmann","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ygyno.2023.07.017_bb0025","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1136\/ijgc-2020-001556","article-title":"Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes","volume":"30","author":"Pietragalla","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2023.07.017_bb0030","doi-asserted-by":"crossref","unstructured":"X. Chen, M.A. Meyer, J.L. Kemppainen, et al., Risk of syndrome-associated cancers among first-degree relatives of patients with pancreatic ductal adenocarcinoma with pathogenic or likely pathogenic germline variants, JAMA Oncol. [Internet] 2023 [cited 2023 Jul 31];9(7):955-961. Available from: https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2805076","DOI":"10.1001\/jamaoncol.2023.0806"},{"issue":"10","key":"10.1016\/j.ygyno.2023.07.017_bb0040","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J. Clin. Epidemiol."},{"issue":"1","key":"10.1016\/j.ygyno.2023.07.017_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.16.00066","article-title":"breast and ovarian cancer penetrance estimates derived from germline multiple-gene sequencing results in women","author":"Kurian","year":"2017","journal-title":"JCO Precis. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2023.07.017_bb0055","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13053-019-0119-3","article-title":"Age-adjusted association of homologous recombination genes with ovarian cancer using clinical exomes as controls","volume":"17","author":"Arvai","year":"2019","journal-title":"Hereditary Cancer Clin. Pract."},{"issue":"2","key":"10.1016\/j.ygyno.2023.07.017_bb0060","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ygyno.2015.12.017","article-title":"Genetic characterization of early onset ovarian carcinoma","volume":"140","author":"Bernards","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2023.07.017_bb0065","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ygyno.2017.04.009","article-title":"Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non-BRCA cancer-associated genes","volume":"146","author":"Frey","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"15","key":"10.1016\/j.ygyno.2023.07.017_bb0075","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1200\/JCO.18.01854","article-title":"Genetic testing and results in a population-based cohort of breast Cancer patients and ovarian Cancer patients","volume":"37","author":"Kurian","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2023.07.017_bb0080","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/jmedgenet-2019-106403","article-title":"Retesting of women who are negative for a BRCA1 and BRCA2 mutation using a 20-gene panel","volume":"57","author":"Lerner-Ellis","year":"2020","journal-title":"J. Med. Genet."},{"issue":"1","key":"10.1016\/j.ygyno.2023.07.017_bb0085","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ygyno.2015.01.537","article-title":"Hereditary predisposition to ovarian cancer, looking beyond BRCA1\/BRCA2","volume":"137","author":"Minion","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2023.07.017_bb0090","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol."},{"issue":"24","key":"10.1016\/j.ygyno.2023.07.017_bb0095","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.20.03661","article-title":"Therapeutic implications of germline testing in patients with advanced cancers","volume":"39","author":"Stadler","year":"2021","journal-title":"JCO"},{"issue":"16","key":"10.1016\/j.ygyno.2023.07.017_bb0100","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1002\/cncr.32083","article-title":"Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer","volume":"125","author":"Weitzel","year":"2019","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2023.07.017_bb0105","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ygyno.2017.08.030","article-title":"Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls","volume":"147","author":"Lilyquist","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2023.07.017_bb0110","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1158\/1078-0432.CCR-21-2861","article-title":"Identification and management of pathogenic variants in BRCA1, BRCA2, and PALB2 in a tumor-only genomic testing program","volume":"28","author":"Bychkovsky","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"44","key":"10.1016\/j.ygyno.2023.07.017_bb0115","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.ygyno.2023.07.017_bb0120","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jamaoncol.2015.2690","article-title":"Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment","volume":"1","author":"Desmond","year":"2015","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2023.07.017_bb0125","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ygyno.2018.09.030","article-title":"Germline pathogenic variants identified in women with ovarian tumors","volume":"151","author":"Carter","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2023.07.017_bb0130","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/gim.2014.40","article-title":"Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients","volume":"16","author":"LaDuca","year":"2014","journal-title":"Genet. Med."},{"key":"10.1016\/j.ygyno.2023.07.017_bb0135","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2350-11-20","article-title":"A novel germline PALB2 deletion in polish breast and ovarian cancer patients","volume":"11","author":"Dansonka-Mieszkowska","year":"2010","journal-title":"BMC Med. Genet."},{"issue":"11","key":"10.1016\/j.ygyno.2023.07.017_bb0140","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3390\/cancers10110442","article-title":"Spectrum and prevalence of pathogenic variants in ovarian Cancer susceptibility genes in a group of 333 patients","volume":"10","author":"Koczkowska","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ygyno.2023.07.017_bb0145","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13053-016-0046-5","article-title":"Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in southern Poland","volume":"14","author":"Wojcik","year":"2016","journal-title":"Hered Cancer Clin. Pract."},{"issue":"1","key":"10.1016\/j.ygyno.2023.07.017_bb0150","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13053-022-00218-0","article-title":"Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor","volume":"20","author":"Ogrodniczak","year":"2022","journal-title":"Hereditary Cancer Clin. Pract."},{"issue":"3","key":"10.1016\/j.ygyno.2023.07.017_bb0155","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10689-017-0050-6","article-title":"Targeted massively parallel sequencing characterises the mutation spectrum of PALB2 in breast and ovarian cancer cases from Poland and Ukraine","volume":"17","author":"Myszka","year":"2018","journal-title":"Familial Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2023.07.017_bb0160","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3390\/cancers13040849","article-title":"Recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in polish patients with ovarian Cancer","volume":"13","author":"\u0141ukomska","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ygyno.2023.07.017_bb0165","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1897-4287-12-19","article-title":"Mutation analysis of PALB2 in BRCA1 and BRCA2-negative breast and\/or ovarian cancer families from eastern Ontario, Canada","volume":"12","author":"Hartley","year":"2014","journal-title":"Hered Cancer Clin. Pract."},{"issue":"1","key":"10.1016\/j.ygyno.2023.07.017_bb0170","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10689-016-9919-z","article-title":"Frequency of germline PALB2 mutations among women with epithelial ovarian cancer","volume":"16","author":"Kotsopoulos","year":"2017","journal-title":"Familial Cancer"},{"key":"10.1016\/j.ygyno.2023.07.017_bb0175","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2350-14-5","article-title":"Contribution of the PALB2 c.2323C>T [p.Q775X] Founder mutation in well-defined breast and\/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent","volume":"14","author":"Tischkowitz","year":"2013","journal-title":"BMC Med. Genet."},{"issue":"2","key":"10.1016\/j.ygyno.2023.07.017_bb0180","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3343\/alm.2020.40.2.148","article-title":"Clinical validity of next-generation Sequencing multi-gene panel testing for detecting pathogenic variants in patients with hereditary breast-ovarian Cancer syndrome","volume":"40","author":"Yoo","year":"2020","journal-title":"Ann. Lab. Med."},{"issue":"3","key":"10.1016\/j.ygyno.2023.07.017_bb0185","doi-asserted-by":"crossref","first-page":"917","DOI":"10.4143\/crt.2017.220","article-title":"Detection of germline mutations in patients with epithelial ovarian cancer using multi-gene panels: beyond BRCA1\/2","volume":"50","author":"Eoh","year":"2018","journal-title":"Cancer Res. Treat."},{"issue":"4","key":"10.1016\/j.ygyno.2023.07.017_bb0190","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2018.29.e43","article-title":"Prevalence of germline BRCA mutations among women with carcinoma of the peritoneum or fallopian tube","volume":"29","author":"Choi","year":"2018","journal-title":"J. Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2023.07.017_bb0195","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv214","article-title":"Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer","volume":"107","author":"Ramus","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.ygyno.2023.07.017_bb0200","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1136\/jmedgenet-2019-106739","article-title":"Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer","volume":"58","author":"Song","year":"2021","journal-title":"J. Med. Genet."},{"issue":"4","key":"10.1016\/j.ygyno.2023.07.017_bb0205","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s10689-013-9620-4","article-title":"The incidence of PALB2 c.3113G>a in women with a strong family history of breast and ovarian cancer attending familial cancer centres in Australia","volume":"12","author":"Teo","year":"2013","journal-title":"Familial Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2023.07.017_bb0210","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s12253-019-00586-4","article-title":"BRCA1 and BRCA2 germline mutation analysis in hereditary breast\/ovarian cancer families from the Aures region (eastern Algeria): first report","volume":"26","author":"Mehemmai","year":"2020","journal-title":"Pathol. Oncol. Res."},{"issue":"3","key":"10.1016\/j.ygyno.2023.07.017_bb0215","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.0307","article-title":"Gene Sequencing for pathogenic variants among adults with breast and ovarian Cancer in the Caribbean","volume":"4","author":"George","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"16","key":"10.1016\/j.ygyno.2023.07.017_bb0220","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.3390\/cancers13164195","article-title":"Germline PALB2 mutation in high-risk Chinese breast and\/or ovarian cancer patients","volume":"13","author":"Kwong","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ygyno.2023.07.017_bb0225","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1136\/ijgc-2018-000017","article-title":"The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer","volume":"29","author":"Hjortkj\u00e6r","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2023.07.017_bb0230","doi-asserted-by":"crossref","first-page":"R20","DOI":"10.1186\/bcr2832","volume":"13","author":"Kuusisto","year":"2011","journal-title":"Breast Cancer Res."},{"issue":"12","key":"10.1016\/j.ygyno.2023.07.017_bb0235","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1038\/s41436-018-0005-9","article-title":"Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families","volume":"20","author":"Cast\u00e9ra","year":"2018","journal-title":"Genet. Med."},{"issue":"10","key":"10.1016\/j.ygyno.2023.07.017_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186043","article-title":"Prevalence of deleterious germline variants in risk genes including BRCA1\/2 in consecutive ovarian cancer patients (AGO-TR-1)","volume":"12","author":"Harter","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ygyno.2023.07.017_bb0245","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jmoldx.2020.01.013","article-title":"Germline mutation in 1338 BRCA-negative Chinese hereditary breast and\/or ovarian Cancer patients: clinical testing with a multigene test panel","volume":"22","author":"Kwong","year":"2020","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.ygyno.2023.07.017_bb0250","article-title":"Exome sequencing in BRCA1-2 candidate familias: the contribution of other cancer susceptibility genes","volume":"11","author":"Doddato","year":"2021","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2023.07.017_bb0255","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s10147-015-0906-4","article-title":"Analysis of PALB2 mutations in 155 Japanese patients with breast and\/or ovarian cancer","volume":"21","author":"Nakagomi","year":"2016","journal-title":"Int. J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2023.07.017_bb0260","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ygyno.2015.11.001","article-title":"Evaluation of germline BRCA1 and BRCA2 mutations in a multi-ethnic Asian cohort of ovarian cancer patients","volume":"141","author":"Hasmad","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2023.07.017_bb0265","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10549-010-1001-1","article-title":"PALB2 analysis in BRCA2-like families","volume":"127","author":"Adank","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.ygyno.2023.07.017_bb0270","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1399-0004.2011.01824.x","article-title":"Rare occurrence of PALB2 mutations in ovarian cancer patients from the Volga-Ural region","volume":"82","author":"Prokofyeva","year":"2012","journal-title":"Clin. Genet."},{"issue":"4","key":"10.1016\/j.ygyno.2023.07.017_bb0275","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3390\/cancers12040956","article-title":"Multigene panel germline testing of 1333 Czech patients with ovarian Cancer","volume":"12","author":"Lhotova","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ygyno.2023.07.017_bb0280","doi-asserted-by":"crossref","first-page":"10086","DOI":"10.1038\/ncomms10086","article-title":"Patterns and functional implications of rare germline variants across 12 cancer types","volume":"6","author":"Lu","year":"2015","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.ygyno.2023.07.017_bb0285","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10549-017-4181-0","article-title":"Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients","volume":"163","author":"Crawford","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.ygyno.2023.07.017_bb0290","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13048-019-0560-y","article-title":"Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study","volume":"12","author":"Li","year":"2019","journal-title":"J. Ovarian. Res."},{"issue":"1","key":"10.1016\/j.ygyno.2023.07.017_bb0295","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/ijc.33317","article-title":"Frequency and molecular characteristics of PALB2-associated cancers in Russian patients","volume":"148","author":"Preobrazhenskaya","year":"2021","journal-title":"Int. J. Cancer"},{"issue":"11\u221212","key":"10.1016\/j.ygyno.2023.07.017_bb0300","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00439-017-1845-0","article-title":"Expanding the spectrum of germline variants in cancer","volume":"136","author":"Siraj","year":"2017","journal-title":"Hum. Genet."},{"issue":"6","key":"10.1016\/j.ygyno.2023.07.017_bb0305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178450","article-title":"Reanalysis of BRCA1\/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability","volume":"12","author":"Stafford","year":"2017","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.ygyno.2023.07.017_bb0310","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/gim.2015.166","article-title":"Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing","volume":"18","author":"Susswein","year":"2016","journal-title":"Genet. Med."},{"issue":"10","key":"10.1016\/j.ygyno.2023.07.017_bb0315","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/s41436-021-01234-6","article-title":"Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer","volume":"23","author":"Woodward","year":"2021","journal-title":"Genet. Med."},{"issue":"7","key":"10.1016\/j.ygyno.2023.07.017_bb0320","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.19.01907","article-title":"Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families","volume":"38","author":"Yang","year":"2020","journal-title":"JCO"},{"issue":"23","key":"10.1016\/j.ygyno.2023.07.017_bb0325","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","article-title":"Gene-panel sequencing and the prediction of breast-cancer risk","volume":"372","author":"Easton","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2023.07.017_bb0330","article-title":"This breast cancer gene is less well known, but nearly as dangerous [internet]","author":"Berger","year":"2001","journal-title":"New York Times"},{"issue":"(1","key":"10.1016\/j.ygyno.2023.07.017_bb0335","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA A Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.ygyno.2023.07.017_bb0340","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2014.09.009","article-title":"Society of gynecologic oncology statement on risk assessment for inherited gynecologic cancer predispositions","volume":"136","author":"Lancaster","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2023.07.017_bb0345","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1200\/OP.21.00382","article-title":"Risk-reducing bilateral Salpingo-oophorectomy for ovarian Cancer: a review and clinical guide for hereditary predisposition genes","volume":"18","author":"Liu","year":"2022","journal-title":"JCO Oncol. Pract."},{"issue":"10","key":"10.1016\/j.ygyno.2023.07.017_bb0350","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/ijgc-2020-001536","article-title":"Management of high, moderate, and low penetrance ovarian cancer susceptibility mutations: an assessment of current risk reduction practices","volume":"30","author":"Watson","year":"2020","journal-title":"Int. J. Gynecol. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582301418X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582301418X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:05:04Z","timestamp":1758773104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082582301418X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":67,"alternative-id":["S009082582301418X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.07.017","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Partner and localizer of BRCA2 (PALB2) pathogenic variants and ovarian cancer: A systematic review and meta-analysis.","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}